

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSING AGREEMENT WITH TIUMBIO

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on August 8, 2022, Hansoh (Shanghai) Healthtech Company Ltd.* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Ltd.* (江蘇豪森藥業集團有限公司) (collectively, the “**Licensees**”), both wholly-owned subsidiaries of the Company, entered into an exclusive license and collaboration agreement (the “**Licensing Agreement**”) with TiumBio Co., Ltd. (“**TiumBio**”).

Pursuant to the Licensing Agreement, the Licensees obtained an exclusive license from TiumBio to develop and commercialize TU2670 for the treatment of endometriosis, uterine fibroids and other indications within China (including Hong Kong, Macau and Taiwan). The Licensees will be responsible for the development, regulatory approval and commercialization of TU2670 in China, and will pay a US\$4.5 million upfront payment, a US\$1.5 million technology transfer payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to US\$164 million, plus tiered royalties on future net product sales.

ABOUT TU2670

TU2670 is an orally active non-peptide GnRH antagonist. Early phase clinical trials have demonstrated excellent safety and tolerability of TU2670.

ABOUT TIUMBIO

Based in South Korea, TiumBio is an R&D-focused biopharmaceutical company dedicated to the discovery and development of innovative small molecule and biologic medicines. The company is currently developing clinical and pre-clinical drug candidates in the areas of immuno-oncology, fibrosis, endometriosis/uterine fibroids, and hemophilia. To the best knowledge and belief of the Company, TiumBio is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 8, 2022

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*